Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling

Head and Neck Squamous Cell Cancer Clinical Trial

Official title:

Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02083692
• Other study ID #: 13D.458
• Status: Completed
• Phase: Early Phase 1
• Start date: September 5, 2013
• Est. completion date: April 6, 2017

Study information

• Verified date: February 2024
• Source: Thomas Jefferson University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effect of metformin in tumor metabolism in patients with head and neck cancer by evaluating metformin's ability to decrease TOMM20 expression in squamous carcinoma cells and decrease MCT4 expression in fibroblasts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: April 6, 2017
• Est. primary completion date: May 9, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH
• Age = 18 years of age and =80 years old.
• Newly diagnosed with HNSCC cancer.
• No prior therapy for HNSCC cancer is permitted for enrollment in the trial.
• All subjects must be able to comprehend and sign a written informed consent document.

Exclusion Criteria:

• Pregnant or may become pregnant during metformin administration.
• On metformin for any reason during the preceding 4 weeks.
• Diabetic patients are eligible if they are not taking metformin, insulin or sulfonylureas.
• Received iodinated contrast dye less than 48 hours prior to screening meet a temporary exclusion criteria to receive metformin. These patients cannot start investigational metformin until 48 hours have elapsed from contrast administration. Subjects who are scheduled for iodinated contrast dye administration within 48 hours of definitive surgery are excluded.
• Plasma alanine aminotransferase greater than 40 IU/dL.
• Plasma aspartate aminotransferase greater than 45 IU/dL.
• Plasma creatinine level greater than 1.3 mg/dL.
• Plasma alkaline phosphatase greater than 190 IU/dL.
• Plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis.
• History of congestive heart failure.
• Myocardial ischemia or peripheral muscle ischemia.
• Sepsis or severe infection.
• History of lung disease currently requiring any pharmacologic or supplemental oxygen treatment.
• Scheduled for definitive HNSCC cancer surgical resection less than two weeks from enrollment or greater than five weeks from enrollment.
• History of hepatic dysfunction or hepatic disease.
• Excessive alcohol intake which is defined in accordance with CDC definitions as more than 1 drink per day for women and more than 2 drinks per day for men. All medications are permitted except those that are contraindicated with metformin under current FDA recommendations.

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Cancer
• Neoplasms, Squamous Cell

Intervention

Drug:
• Metformin

Locations

Country	Name	City	State
United States	Thomas Jefferson University	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Sidney Kimmel Cancer Center at Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in TOMM20 and MCT4 expression from tumor cells from date of biopsy and date of surgery		date of biopsy and date of surgery (9-28 days)

External Links

•   Thomas Jefferson University Hospital